These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34773164)

  • 1. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.
    Hong CM; Shin JY; Kim BI; Song HC; Yoon JK; Won KS; Kim SM; Cho IH; Jeong SY; Lee SW; Lee J
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1661-1670. PubMed ID: 34773164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
    Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
    Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
    Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
    Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
    Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
    Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
    Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
    Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
    Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
    Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
    Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
    Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
    Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
    Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
    World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.
    Kim S; Bang JI; Boo D; Kim B; Choi IY; Ko S; Yoo IR; Kim K; Kim J; Joo Y; Ryoo HG; Paeng JC; Park JM; Jang W; Kim B; Chung Y; Yang D; Yoo S; Lee HY
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3547-3556. PubMed ID: 35362796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of thyroid hormone replacement on the risk of second cancer after thyroidectomy: a Korean National Cohort Study.
    Ho J; Han M; Jung I; Jo YS; Lee J
    Sci Rep; 2023 Sep; 13(1):16280. PubMed ID: 37770542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
    Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
    Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.